MECHANISM OF ACTION AND ADVERSE REACTIONS OF ANTIVIRALS RECOMMENDED FOR HEPATITIS C IN BRAZIL

Authors

DOI:

https://doi.org/10.14450/2318-9312.v33.e2.a2021.pp149-157

Keywords:

Hepatitis C, pangenotypic drugs, antiviral drugs.

Abstract

Hepatitis C is a disease that affects the entire world population, also affecting the population’s quality of life. The use of medications is  fundamental for the therapeutic process of patients with hepatitis C. The  treatment of hepatitis C faced several obstacles with the viral pangenotypic  diversity and the adverse treatment reactions faced by those infected with  the vírus. However, over the years, the evolution of the pharmaceutical  market and antiviral drugs has occurred in several research fields against  hepatitis C. In this context, it is important to understand the mechanisms of  action and adverse reactions of the drugs used to treat hepatitis C in Brazil.  The research is a bibliographic review, through a survey of scientific articles  in the databases LILACs, Pubmed, Google Acadêmico, and SciELO, ordinances, and bulletins from the Ministry of Health. Molecular  improvements of the drugs aim to decrease the treatment time, thus  increasing patient compliance because these new drugs have mild adverse  effects. Concerning the treatment of hepatitis C, the pharmaceutical industry trend is to produce pangenotypic drugs, that is, that act in all HCV genotypes.

Downloads

Published

2021-06-30

How to Cite

Araújo Júnior, J. R. R. de, Silva, A. A. de C. da, & Souza, S. C. S. de. (2021). MECHANISM OF ACTION AND ADVERSE REACTIONS OF ANTIVIRALS RECOMMENDED FOR HEPATITIS C IN BRAZIL. Infarma - Pharmaceutical Sciences, 33(2), 149–157. https://doi.org/10.14450/2318-9312.v33.e2.a2021.pp149-157

Issue

Vol. 33 No. 2 (2021)

Section

Review Article

License

Authors who publish in this journal agree to the following terms:

 

  1. Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
  2. Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
  3. Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).